Kite wins FDA approval for first adult CAR-T cell therapy

More than a month before it was due to make a decision, the FDA yesterday approved a CAR-T cell therapy from Kite Pharma (NSDQ:KITE) – the first of its kind for adults.
The therapy, which is made from a patient’s own cells, is designed to treat adults with non-Hodgkin lymphoma who have failed at least two other treatments.
Get the full story at our sister site, Drug Delivery Business News.
The post Kite wins FDA approval for first adult CAR-T cell therapy appeared first on MassDevice.

Source: Mass Device - October 19, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Oncology Regulatory/Compliance Wall Street Beat Gilead Sciences kitepharma Source Type: news